Home » U.S. Approves Spectrum Pharma’s Purchase of Allos

U.S. Approves Spectrum Pharma’s Purchase of Allos

September 4, 2012

U.S. antitrust officials have approved Spectrum Pharmaceuticals’ purchase of cancer drugmaker Allos Therapeutics, a $206 million deal aimed at giving Spectrum access to the Allos anti-cancer drug Folotyn.
Reuters

21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean

U.S. Approves Spectrum Pharma’s Purchase of Allos

Upcoming Events

Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

FDA Clears SCC’s Transfusion-Management Software

The Revised ICH E8: A Guide to New Clinical Trial Requirements